GPOs began emerging in 2019 and continue to grow. In this Fast Five, we share five insights on transparency in the age of GPOs and what to keep in mind when you are evaluating different PBMs. 

The Fast Five: Transparency in the Age of GPOs

While some pharmacy benefit managers (PBMs) have been talking about transparency for years, it has become an increasingly hot topic in the health care industry. So what does transparency really mean? Let’s take a fast five (minutes) to look at PBM pricing models and how transparency comes into play.

The Fast Five: Let’s Be Clear. What Does Transparency Mean in PBM Pricing?

Everyone is hearing a lot about prescription drug pricing lately thanks to a very famous billionaire entrepreneur. What is cost-plus pricing? Is it new? How is it disrupting the industry? In this Fast Five, we share answers to these questions and provide guidance on how to evaluate this model. For a smart insider’s perspective, we consulted with Sharon Faust, Senior Vice President, Lumicera Specialty Pharmacy. 

The Fast Five: Drug Pricing Disruptors

Biosimilars are a hot topic in the pharmacy industry right now. Wondering what all the buzz is about?   In this Fast Five, we asked our clinical experts, Janelle Sheen and Imke Scheepers, to share the basics about biosimilars as well as some key insights on this topic.  

The Fast Five: What’s all the Buzz about Biosimilars? 

Our Vice President of Sales, Jonathan Har-Even, shares his outlook on the industry and where we need to go next. He discusses 5 ways the PBM industry can continue to improve and promote better healthcare for all, including a 5-year plan that uses lowest net cost as a foundation and builds out a platform for payors, members, and pharmacists.

The Fast Five: Beyond Transparency

Does your PBM provide transparent contracts and reporting? It is time to move PBM business intelligence out of the dark ages. This white paper is the third in a series dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.

Information Disadvantages Created by PBMs
Load More
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now